“Most affordable” here means the lowest advertised semaglutide price. Some figures are provider-published and some are secondary; each is labeled. Compounded semaglutide is not FDA-approved.
Ranked by lowest advertised semaglutide price. Membership and dose terms vary — check total cost, not just the headline.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Lowest advertised | Notes | Provenance |
|---|---|---|---|
| Mochi Health | ~$99 (add-on) | Plus required ~$79 membership; total higher | secondary |
| Fifty 410 | ~$99 (3-mo) / ~$199 (m2m) | Dose-tiered; reported | secondary |
| NexLife | ~$145 (12-mo) / $165 (m2m) | Flat; no membership (stated) | primary |
Headline semaglutide prices around $99 typically require a multi-month prepay or carry a separate membership, so compare the total. NexLife’s ~$145–$165 is flat with no membership (provider-stated). Several figures here are secondary and pending live re-verification.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.